Prime Clinical Research, Inc
Welcome,         Profile    Billing    Logout  
 0 Trials 
10 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Calcagno, Frank
NCT04759833 / 2022-003221-22: A Study of Prucalopride For Functional Constipation in Children and Teenagers

Terminated
3
175
US
Prucalopride, TAK-555, Prucalopride succinate, Placebo
Takeda, Takeda Development Center Americas, Inc.
Constipation
11/23
11/23
NCT05412030: A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

Active, not recruiting
2
472
US
AFX3772, Prevnar 13, PCV13, Prevnar 20, PCV20
GlaxoSmithKline, Affinivax, Inc.
Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
07/26
07/26
NCT06720038: A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

Recruiting
2
800
US
0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20
Vaxcyte, Inc.
Pneumococcal Vaccines
06/27
06/27
ASPIRE-2, NCT05506618: Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag ULTRA Test

Active, not recruiting
N/A
400
US
Nasal Swab, Nasopharyngeal swab
LumiraDx UK Limited
COVID-19
10/22
04/23
NCT05947084: Comparison of Growth and Tolerance of Healthy Term Infants Fed Iron-Fortified Infant Formulas

Completed
N/A
518
US
Infant Formula
Aussie Bubs, Inc., Validcare
Infant Development
04/25
06/25
Zulich, Ronda
NCT05947084: Comparison of Growth and Tolerance of Healthy Term Infants Fed Iron-Fortified Infant Formulas

Completed
N/A
518
US
Infant Formula
Aussie Bubs, Inc., Validcare
Infant Development
04/25
06/25
Twan, Steven
NCT05947084: Comparison of Growth and Tolerance of Healthy Term Infants Fed Iron-Fortified Infant Formulas

Completed
N/A
518
US
Infant Formula
Aussie Bubs, Inc., Validcare
Infant Development
04/25
06/25
Romero, Jerrian
NCT05947084: Comparison of Growth and Tolerance of Healthy Term Infants Fed Iron-Fortified Infant Formulas

Completed
N/A
518
US
Infant Formula
Aussie Bubs, Inc., Validcare
Infant Development
04/25
06/25
Lackey, Jessica
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT05947084: Comparison of Growth and Tolerance of Healthy Term Infants Fed Iron-Fortified Infant Formulas

Completed
N/A
518
US
Infant Formula
Aussie Bubs, Inc., Validcare
Infant Development
04/25
06/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Calcagno, Frank
NCT04759833 / 2022-003221-22: A Study of Prucalopride For Functional Constipation in Children and Teenagers

Terminated
3
175
US
Prucalopride, TAK-555, Prucalopride succinate, Placebo
Takeda, Takeda Development Center Americas, Inc.
Constipation
11/23
11/23
NCT05412030: A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

Active, not recruiting
2
472
US
AFX3772, Prevnar 13, PCV13, Prevnar 20, PCV20
GlaxoSmithKline, Affinivax, Inc.
Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
07/26
07/26
NCT06720038: A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

Recruiting
2
800
US
0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20
Vaxcyte, Inc.
Pneumococcal Vaccines
06/27
06/27
ASPIRE-2, NCT05506618: Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag ULTRA Test

Active, not recruiting
N/A
400
US
Nasal Swab, Nasopharyngeal swab
LumiraDx UK Limited
COVID-19
10/22
04/23
NCT05947084: Comparison of Growth and Tolerance of Healthy Term Infants Fed Iron-Fortified Infant Formulas

Completed
N/A
518
US
Infant Formula
Aussie Bubs, Inc., Validcare
Infant Development
04/25
06/25
Zulich, Ronda
NCT05947084: Comparison of Growth and Tolerance of Healthy Term Infants Fed Iron-Fortified Infant Formulas

Completed
N/A
518
US
Infant Formula
Aussie Bubs, Inc., Validcare
Infant Development
04/25
06/25
Twan, Steven
NCT05947084: Comparison of Growth and Tolerance of Healthy Term Infants Fed Iron-Fortified Infant Formulas

Completed
N/A
518
US
Infant Formula
Aussie Bubs, Inc., Validcare
Infant Development
04/25
06/25
Romero, Jerrian
NCT05947084: Comparison of Growth and Tolerance of Healthy Term Infants Fed Iron-Fortified Infant Formulas

Completed
N/A
518
US
Infant Formula
Aussie Bubs, Inc., Validcare
Infant Development
04/25
06/25
Lackey, Jessica
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT05947084: Comparison of Growth and Tolerance of Healthy Term Infants Fed Iron-Fortified Infant Formulas

Completed
N/A
518
US
Infant Formula
Aussie Bubs, Inc., Validcare
Infant Development
04/25
06/25

Download Options